Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength

FEBS Journal

Volumn 280, Issue 21, 2013, Pages 5337-5349

  Smith, Greg C ^a   Ong, Wee Kiat ^b   Costa, Jessica L ^a   Watson, Maureen ^a   Cornish, Jillian ^a   Grey, Andrew ^a   Gamble, Greg D ^a   Dickinson, Michelle ^a   Leung, Sophie ^a   Rewcastle, Gordon W ^c   Han, Weiping ^b   Shepherd, Peter R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AGENCY FOR SCIENCE   (Singapore)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

A66; BEZ235; phosphatidylinositol 3 kinase; PIK75; ZSTK474

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHENMETRAZINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; PROTEIN P110; PROTEIN P110ALPHA ISOFORM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BASAL METABOLIC RATE; BODY COMPOSITION; BONE DENSITY; BONE MASS; BONE STRENGTH; CONFERENCE PAPER; CONTROLLED STUDY; FLUID INTAKE; FOOD INTAKE; GLUCOSE METABOLISM; GROWTH; INSULIN TOLERANCE TEST; LOCOMOTION; LONG TERM EXPOSURE; MALE; METABOLISM; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL;

A66; BEZ235; PHOSPHATIDYLINOSITOL 3-KINASE; PIK75; ZSTK474;

ANIMALS; BASAL METABOLISM; BEHAVIOR, ANIMAL; BODY COMPOSITION; BODY MASS INDEX; BONE AND BONES; BONE DENSITY; EATING; GLUCOSE; IMIDAZOLES; INSULIN; MALE; MICE; MICE, INBRED C57BL; OXYGEN CONSUMPTION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84886083369     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12428     Document Type: Conference Paper

References (51)

1. Vanhaesebroeck B, Stephens L, &, Hawkins P, (2012) PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13, 195-203.
2. Gonzalez E, &, McGraw TE, (2009) The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 8, 2502-2508.
3. Lemmon MA, (2008) Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 9, 99-111.
4. Shepherd PR, Withers DJ, &, Siddle K, (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 333, 471-490.
5. Foukas LC, &, Withers DJ, (2010) Phosphoinositide signalling pathways in metabolic regulation. Curr Top Microbiol Immunol 346, 115-141.
6. Shepherd PR, (2005) Mechanisms regulating phosphoinositide 3-kinase signalling in insulin sensitive tissues. Acta Physiol Scand 183, 3-12.
7. Welsh GI, Hers I, Berwick DC, Dell G, Wherlock M, Birkin R, Leney S, &, Tavare JM, (2005) Role of protein kinase B in insulin-regulated glucose uptake. Biochem Soc Trans 33, 346-349.
8. Watson RT, &, Pessin JE, (2006) Bridging the GAP between insulin signaling and GLUT4 translocation. Trends Biochem Sci 31, 215-222.
9. Hill MM, Clark SF, Tucker DF, Birnbaum MJ, James DE, &, Macaulay SL, (1999) A role for protein kinase Bbeta/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes. Mol Cell Biol 19, 7771-7781.
10. Gonzalez E, &, McGraw TE, (2006) Insulin signaling diverges into Akt-dependent and -independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. Mol Biol Cell 17, 4484-4493.
11. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR, &, Klip A, (1999) Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell Biol 19, 4008-4018.
12. Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, et al,. (2012) Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet 44, 928-933.
13. Becattini B, Marone R, Zani F, Arsenijevic D, Seydoux J, Montani JP, Dulloo AG, Thorens B, Preitner F, Wymann MP, et al,. (2011) PI3Kgamma within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc Natl Acad Sci USA 108, E854-E863.
14. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskitt E, Sancho S, Smith AJH, Withers DJ, &, VanHaesebroeck B, (2006) Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370.
15. Kim JE, Shepherd PR, &, Chaussade C, (2009) Investigating the role of class-IA PI3-kinase isoforms in adipocyte differentiation. Biochem Biophys Res Commun 379, 830-834.
16. Kaliman P, Vinals F, Testar X, Palacin M, &, Zorzano A, (1996) Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. J Biol Chem 271, 19146-19151.
17. Guntur AR, &, Rosen CJ, (2011) The skeleton: a multi-functional complex organ: new insights into osteoblasts and their role in bone formation: the central role of PI3Kinase. J Endocrinol 211, 123-130.
18. Kang H, Chang W, Hurley M, Vignery A, &, Wu D, (2010) Important roles of PI3Kgamma in osteoclastogenesis and bone homeostasis. Proc Natl Acad Sci USA 107, 12901-12906.
19. Toyama S, Tamura N, Haruta K, Karakida T, Mori S, Watanabe T, Yamori T, &, Takasaki Y, (2010) Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. Arthrit Res Ther 12, R92.
20. Martin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, Shepherd PR, &, Zannettino AC, (2010) NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res 25, 2126-2137.
21. Grey A, Chaussade C, Empson V, Lin JM, Watson M, O'Sullivan S, Rewcastle G, Naot D, Cornish J, &, Shepherd P, (2010) Evidence for a role for the p110-alpha isoform of PI3K in skeletal function. Biochem Biophys Res Commun 391, 564-569.
22. Bandaru SS, Lin K, Roming SL, Vellipuram R, &, Harney JP, (2010) Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior. Physiol Behav 100, 239-244.
23. Kurtz JE, &, Ray-Coquard I, (2012) PI3 kinase inhibitors in the clinic: an update. Anticancer Res 32, 2463-2470.
24. Chen L, Xing T, Wang M, Miao Y, Tang M, Chen J, Li G, &, Ruan DY, (2011) Local infusion of ghrelin enhanced hippocampal synaptic plasticity and spatial memory through activation of phosphoinositide 3-kinase in the dentate gyrus of adult rats. Eur J Neurosci 33, 266-275.
25. Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, Cristiano BE, Pearson RB, &, Phillips WA, (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64, 7678-7681.
26. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al,. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554.
27. Carson JD, Van Aller G, Lehr R, Sinnamon RH, Kirkpatrick RB, Auger KR, Dhanak D, Copeland RA, Gontarek RR, Tummino PJ, et al,. (2008) Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 409, 519-524.
28. Chaussade C, Cho K, Mawson C, Rewcastle GW, &, Shepherd PR, (2009) Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem Biophys Res Commun 381, 577-581.
29. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Gronning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, et al,. (2007) Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 404, 449-558.
30. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, et al,. (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signalling. Cell 125, 1-15.
31. Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, &, Workman P, (2011) Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem 18, 2686-2714.
32. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, Mikami A, &, Roberts TM, (2006) The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 103, 16296-16300.
33. Bi L, Okabe I, Bernard DJ, &, Nussbaum RL, (2002) Early embryonic lethality in mice deficient in the p110 beta catalytic subunit of PI 3-kinase. Mamm Genome 13, 169-172.
34. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, et al,. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454, 776-779.
35. Sopasakis VR, Liu P, Suzuki R, Kondo T, Winnay J, Tran TT, Asano T, Smyth G, Sajan MP, Farese RV, et al,. (2010) Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metab 11, 220-230.
36. Weiss WA, Taylor SS, &, Shokat KM, (2007) Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol 3, 739-744.
37. Smith GC, Ong WK, Rewcastle GW, Kendall JD, Han W, &, Shepherd PR, (2012) Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J 442, 161-169.
38. Liu X, Bruxvoort KJ, Zylstra CR, Liu J, Cichowski R, Faugere MC, Bouxsein ML, Wan C, Williams BO, &, Clemens TL, (2007) Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 104, 2259-2264.
39. Tups A, Anderson GM, Rizwan M, Augustine RA, Chaussade C, Shepherd PR, &, Grattan DR, (2010) Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus. J Neuroendocrinol 22, 534-542.
40. Al-Qassab H, Smith MA, Irvine EE, Guillermet-Guibert J, Claret M, Choudhury AI, Selman C, Piipari K, Clements M, Lingard S, et al,. (2009) Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. Cell Metab 10, 343-354.
41. Kritman M, &, Maroun M, (2012) Inhibition of the PI3 kinase cascade in corticolimbic circuit: temporal and differential effects on contextual fear and extinction. Int J Neuropsychopharmacol 16, 1-9.
42. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et al,. (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30, 282-290.
43. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG, et al,. (2003) Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17, 1352-1365.
44. Ulici V, Hoenselaar KD, Agoston H, McErlain DD, Umoh J, Chakrabarti S, Holdsworth DW, &, Beier F, (2009) The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. Bone 45, 1133-1145.
45. Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, Saito T, Shinoda Y, Kawasaki Y, Ogata N, Hoshi K, et al,. (2007) Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS ONE 2, e1058.
46. Foukas LC, Bilanges B, Bettedi L, Pearce W, Ali K, Sancho S, Withers DJ, &, Vanhaesebroeck B, (2013) Long-term p110alpha PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol Med 5, 563-571.
47. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, Rewcastle GW, Denny WA, Singh R, Dickson J, et al,. (2011) A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 438, 53-62.
48. Lou PH, Yang G, Huang L, Cui Y, Pourbahrami T, Radda GK, Li C, &, Han W, (2010) Reduced body weight and increased energy expenditure in transgenic mice over-expressing soluble leptin receptor. PLoS ONE 5, e11669.
49. Butler AA, &, Kozak LP, (2010) A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes. Diabetes 59, 323-329.
50. Williams GA, Wang Y, Callon KE, Watson M, Lin JM, Lam JB, Costa JL, Orpe A, Broom N, Naot D, et al,. (2009) In vitro and in vivo effects of adiponectin on bone. Endocrinology 150, 3603-3610.
51. Williams GA, Callon KE, Watson M, Costa JL, Ding Y, Dickinson M, Wang Y, Naot D, Reid IR, &, Cornish J, (2011) Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res 26, 1698-1709.